Literature DB >> 25696915

HIV-associated non-Hodgkin lymphoma: viral origins and therapeutic options.

Amrita Krishnan1, John A Zaia2.   

Abstract

HIV infection is associated with an increased risk of malignancy, especially B-cell lymphoid malignancies. Many of these lymphomas are further driven by concomitant infection with viruses such as Epstein-Barr virus or Human Herpesvirus 8, the latter being implicated in uncommon types of lymphomas seen in the setting of HIV-1 infection. Treatment outcomes have improved due to infusional chemotherapy, high-dose chemotherapy, and effective antiretroviral therapy. Successful functional cure of HIV-1 infection has been demonstrated with the use of allogeneic hematopoietic stem cell transplantation. This result spurred a change in the field of HIV-1 management so that, ultimately, the goals of therapy would shift from not only curing the underlying lymphoma, but also curing the HIV-1 infection. Treatment options will be discussed with an emphasis on hematopoietic cell-based therapy for the underlying HIV infection.
© 2014 by The American Society of Hematology. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25696915     DOI: 10.1182/asheducation-2014.1.584

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  3 in total

1.  Racial and ethnic differences in diffuse large B-cell lymphoma survival among an underserved, urban population.

Authors:  Deanna Blansky; Melissa Fazzari; Ioannis Mantzaris; Thomas Rohan; H Dean Hosgood
Journal:  Leuk Lymphoma       Date:  2020-10-28

2.  Fatal Infections Among Cancer Patients: A Population-Based Study in the United States.

Authors:  Yongqiang Zheng; Ying Chen; Kaixu Yu; Yun Yang; Xindi Wang; Xue Yang; Jiaxin Qian; Ze-Xian Liu; Bian Wu
Journal:  Infect Dis Ther       Date:  2021-03-24

3.  Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem/progenitor cells.

Authors:  David L DiGiusto; Paula M Cannon; Michael C Holmes; Lijing Li; Anitha Rao; Jianbin Wang; Gary Lee; Philip D Gregory; Kenneth A Kim; Samuel B Hayward; Kathleen Meyer; Colin Exline; Evan Lopez; Jill Henley; Nancy Gonzalez; Victoria Bedell; Rodica Stan; John A Zaia
Journal:  Mol Ther Methods Clin Dev       Date:  2016-11-09       Impact factor: 6.698

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.